Home LiteratureArticle Details
PMID: 20871975 Published · ppublish English Journal Article Review

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Diabetologia ·Vol. 54 ·No. 1 ·2011-01-00 ·Pages 10-8

Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ

Abstract

The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.

MeSH Terms
Animals Diabetes Mellitus, Type 2/metabolism Glucagon-Like Peptide 1/metabolism Humans Incretins/metabolism Meta-Analysis as Topic Models, Biological
Chemicals
Incretins Glucagon-Like Peptide 1
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Nauck M A
Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany. M.Nauck@diabeteszentrum.de
Vardarli I
Deacon C F
Holst J J
Meier J J
References (68)
68 references, click to expand
  1. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
    Endocrinology. 1993 Jul;133(1):233-40 PMID: 8319572
  2. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes.
    Diabetes Care. 2009 Sep;32(9):1600-2 PMID: 19542012
  3. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
    J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23 PMID: 11502801
  4. Attenuated GLP-1 secretion in obesity: cause or consequence?
    Gut. 1996 Jun;38(6):916-9 PMID: 8984033
  5. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
    Diabetes Care. 2002 Aug;25(8):1398-404 PMID: 12145241
  6. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia.
    Diabetes. 2001 May;50(5):1030-8 PMID: 11334405
  7. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
    Biochem Biophys Res Commun. 2002 Nov 15;298(5):779-84 PMID: 12419322
  8. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut.
    Endocrinology. 1996 Jun;137(6):2383-8 PMID: 8641190
  9. Gut hormones and diabetes mellitus.
    Diabetes Metab Rev. 1992 Jul;8(2):149-77 PMID: 1425125
  10. Exenatide pharmacokinetics in healthy Chinese subjects.
    Int J Clin Pharmacol Ther. 2008 Sep;46(9):459-65 PMID: 18793576
  11. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.
    Endocrinology. 1999 Apr;140(4):1687-94 PMID: 10098504
  12. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
    Diabetologia. 2005 Apr;48(4):612-5 PMID: 15759106
  13. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.
    Diabetes Care. 2001 Sep;24(9):1640-5 PMID: 11522713
  14. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.
    Diabetes. 2009 May;58(5):1058-66 PMID: 19208912
  15. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Regul Pept. 2004 Nov 15;122(3):209-17 PMID: 15491793
  16. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    J Clin Invest. 1993 Jan;91(1):301-7 PMID: 8423228
  17. Colocalization of GLP-1 and GIP in human and porcine intestine.
    Ann N Y Acad Sci. 2000;921:469-72 PMID: 11193878
  18. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.
    Diabetes. 2001 Aug;50(8):1720-8 PMID: 11473030
  19. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.
    Dig Dis Sci. 1991 Oct;36(10):1361-70 PMID: 1914756
  20. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Diabetologia. 1993 Aug;36(8):741-4 PMID: 8405741
  21. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
    Am J Clin Nutr. 2009 Jan;89(1):106-113 PMID: 19056578
  22. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells.
    Endocrinology. 2003 Jul;144(7):3244-50 PMID: 12810581
  23. Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion.
    J Clin Endocrinol Metab. 2010 Feb;95(2):879-86 PMID: 19837920
  24. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Z Gastroenterol. 1996 Mar;34(3):159-66 PMID: 8650968
  25. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Diabet Med. 1998 Jun;15(6):485-91 PMID: 9632123
  26. Glucagon-like peptide-1 7-36: a physiological incretin in man.
    Lancet. 1987 Dec 5;2(8571):1300-4 PMID: 2890903
  27. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Exp Clin Endocrinol Diabetes. 1997;105(4):187-95 PMID: 9285204
  28. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides.
    J Endocrinol. 1995 Oct;147(1):25-31 PMID: 7490533
  29. Incretins and their analogues as new antidiabetic drugs.
    Drug News Perspect. 2003 Sep;16(7):413-22 PMID: 14668937
  30. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13 PMID: 12788877
  31. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
    Diabetes. 1994 Apr;43(4):535-9 PMID: 8138058
  32. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors.
    J Clin Endocrinol Metab. 1997 Mar;82(3):786-90 PMID: 9062483
  33. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Lancet. 2006 Nov 11;368(9548):1696-705 PMID: 17098089
  34. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Diabetes. 2003 Feb;52(2):380-6 PMID: 12540611
  35. The potential role of glucagon-like peptide 1 in diabetes.
    Curr Opin Investig Drugs. 2004 Apr;5(4):402-10 PMID: 15134281
  36. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.
    Eur J Clin Invest. 1992 Apr;22(4):283-91 PMID: 1499644
  37. Neural regulation of glucagon-like peptide-1 secretion in pigs.
    Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E939-47 PMID: 15475512
  38. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
    J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60 PMID: 11502823
  39. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
    Diabetes. 2001 Mar;50(3):609-13 PMID: 11246881
  40. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.
    Horm Metab Res. 2008 Jun;40(6):427-30 PMID: 18401832
  41. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
    Diabetes. 2007 Aug;56(8):1951-9 PMID: 17513701
  42. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
    J Clin Invest. 1991 Feb;87(2):415-23 PMID: 1991827
  43. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
    Diabetes. 2008 May;57(5):1340-8 PMID: 18162504
  44. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
    Diabetologia. 1986 Jan;29(1):46-52 PMID: 3514343
  45. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Regul Pept. 2005 Jun 15;128(2):135-48 PMID: 15780433
  46. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
    Diabetes Res Clin Pract. 1992 Mar;15(3):187-95 PMID: 1576919
  47. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Int J Biochem Cell Biol. 2006;38(5-6):831-44 PMID: 16242377
  48. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
    Diabet Med. 1993 Jan-Feb;10(1):44-9 PMID: 8435987
  49. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.
    Endocrinology. 1986 Oct;119(4):1467-75 PMID: 3530719
  50. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.
    Am J Physiol. 1995 May;268(5 Pt 1):E949-55 PMID: 7762650
  51. Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.
    Proc Natl Acad Sci U S A. 1984 Aug;81(16):5007-11 PMID: 6382256
  52. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
    J Clin Endocrinol Metab. 2010 Aug;95(8):4061-5 PMID: 20501678
  53. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120.
    Nat Med. 2005 Jan;11(1):90-4 PMID: 15619630
  54. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Diabetes. 2008 Mar;57(3):678-87 PMID: 18057091
  55. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
    Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15069-74 PMID: 17724330
  56. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E550-9 PMID: 16219666
  57. DPP-4 inhibitors.
    Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):517-33 PMID: 18054733
  58. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Am J Health Syst Pharm. 2005 Jan 15;62(2):173-81 PMID: 15700891
  59. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery.
    Diabetes Care. 2009 Mar;32(3):375-80 PMID: 19033407
  60. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
    Regul Pept. 2004 Apr 15;118(1-2):11-8 PMID: 14759551
  61. Gastric emptying and release of incretin hormones after glucose ingestion in humans.
    J Clin Invest. 1996 Jan 1;97(1):92-103 PMID: 8550855
  62. Incretin hormones--an update.
    Scand J Clin Lab Invest Suppl. 2001;234:75-85 PMID: 11713984
  63. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.
    Digestion. 1995;56(6):493-501 PMID: 8536820
  64. Carbohydrate digestion and absorption.
    Gastroenterology. 1970 Jan;58(1):96-107 PMID: 4903350
  65. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.
    Horm Metab Res. 2002 Mar;34(3):150-4 PMID: 11972305
  66. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
    Eur J Endocrinol. 2006 Sep;155(3):485-93 PMID: 16914604
  67. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Diabetes Obes Metab. 2002 Sep;4(5):329-35 PMID: 12190996
  68. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides.
    Endocrinology. 1991 Jun;128(6):3175-82 PMID: 1674688
Article Info
Journal
Diabetologia
Abbr.
Diabetologia
ISSN
1432-0428
DOI
10.1007/s00125-010-1896-4
Email
m.nauck@diabeteszentrum.de
Published
2011-01-00
Epub
2010-00-25
Pages
10-8
Language
English
Region
Germany
NLM ID
0006777
Subset
IM
External Links
PubMed source DOI: 10.1007/s00125-010-1896-4 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2